Young-Hwa Chung, Guohong Han, Jung-Hwan Yoon, Jijin Yang, Jianhua Wang, Guo-Liang Shao, Byung Ik Kim, Teng-Yu Lee and Yee Chao Interim analysis of START: Study in asia of the combination of TACE (transcatheter arterial chemoembolization) with sorafenib in patients with hepatocellular carcinoma trial International Journal of Cancer 132
Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide, with the highest incidence occurring in regions like the South-east Asian countries. Transarterial chemoembolization (TACE) is currently a first-line, noncurative therapy for HCC while sorafenib is an effective and safe monotherapy in patients with advanced HCC. The current study reports results from a Phase II trial investigating the safety and efficacy of the combination of sorafenib and conventional TACE in patients with intermediate HCC. The results indicate that the combination is safe, efficacious and provides tangible benefits in terms of response to disease and time to progression.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf